| 000 | 01798 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250513204125.0 | ||
| 264 | 0 | _c20000413 | |
| 008 | 200004s 0 0 eng d | ||
| 022 | _a0022-2623 | ||
| 024 | 7 |
_a10.1021/jm9904607 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNacro, K | |
| 245 | 0 | 0 |
_aConformationally constrained analogues of diacylglycerol (DAG). 16. How much structural complexity is necessary for recognition and high binding affinity to protein kinase C? _h[electronic resource] |
| 260 |
_bJournal of medicinal chemistry _cMar 2000 |
||
| 300 |
_a921-44 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_a4-Butyrolactone _xanalogs & derivatives |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xchemical synthesis |
| 650 | 0 | 4 | _aBinding, Competitive |
| 650 | 0 | 4 | _aCrystallography, X-Ray |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 | _aDrug Screening Assays, Antitumor |
| 650 | 0 | 4 | _aEnzyme Activation |
| 650 | 0 | 4 |
_aEpidermal Growth Factor _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aIsoenzymes _xchemistry |
| 650 | 0 | 4 | _aLigands |
| 650 | 0 | 4 | _aModels, Molecular |
| 650 | 0 | 4 |
_aProtein Kinase C _xchemistry |
| 650 | 0 | 4 | _aProtein Kinase C-alpha |
| 650 | 0 | 4 | _aStereoisomerism |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 650 | 0 | 4 |
_aValerates _xchemical synthesis |
| 700 | 1 | _aBienfait, B | |
| 700 | 1 | _aLee, J | |
| 700 | 1 | _aHan, K C | |
| 700 | 1 | _aKang, J H | |
| 700 | 1 | _aBenzaria, S | |
| 700 | 1 | _aLewin, N E | |
| 700 | 1 | _aBhattacharyya, D K | |
| 700 | 1 | _aBlumberg, P M | |
| 700 | 1 | _aMarquez, V E | |
| 773 | 0 |
_tJournal of medicinal chemistry _gvol. 43 _gno. 5 _gp. 921-44 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1021/jm9904607 _zAvailable from publisher's website |
| 999 |
_c10669066 _d10669066 |
||